Actively Recruiting
StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2
Led by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Updated on 2026-01-14
12
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
Sponsors
A
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead Sponsor
D
Dutch Heart Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Ventricular tachycardia (VT) is a malignant cardiac arrhythmia subjecting our patients to a high risk of sudden death, increased morbidity and reduced quality of life. Unfortunately, failure of treatment is common and VT recurrences remain an important concern. In these patients, stereotactic arrhythmia radiotherapy appears to be an effective and safe treatment. The mechanism of action however remains unknown and should be elucidated. The objective of this phase 2, single arm, monocenter, pre-post intervention study is to evaluate the efficacy and safety of stereotactic arrhythmia radiotherapy and obtain insights in the mechanism of action by evaluating electro-anatomical alterations of stereotactic arrhythmia radiotherapy in patients with therapy refractory ventricular tachycardia.
CONDITIONS
Official Title
StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Implanted implantable cardioverter defibrillator (ICD)
- WHO/ECOG performance status grade 0-3 in the past 3 months
- At least 3 episodes of treated ventricular tachycardia within the last 3 months
- Recurrence of ventricular tachycardia after failed or intolerant to at least one class 1 or class 3 anti-arrhythmic drug AND at least one catheter ablation procedure OR considered unsuitable for catheter ablation
- Able and willing to undergo all necessary evaluations, treatment, and follow-up for the study and afterward
You will not qualify if you...
- Pregnancy
- History of radiation treatment in the thorax or upper abdominal region
- Interstitial pulmonary disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Amsterdam UMC location University of Amsterdam
Amsterdam, North Holland, Netherlands, 1105AZ
Actively Recruiting
Research Team
P
Pieter G Postema, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here